GALECTIN THERAPEUTICS INC — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
This is Galectin Therapeutics' Q3 2026 10-Q quarterly report (period ending 2026-09-30), filed 2026-11-16. The filing document index shows standard SEC exhibits and XBRL data files. No specific financial results, deal announcements, capital raises, partnerships, or material operational changes are stated in the header or metadata provided.
Why this rating
Routine quarterly filing; no substantive business events disclosed in available text excerpt. Standard SEC disclosure mechanics only.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.